SEC Comment Letter 0000000000-23-008778 to Immunome Inc. (IMNM) (CIK 0001472012) (IMNM)
Immunome Inc. (IMNM) (CIK 0001472012)
Date: Aug. 11, 2023 · CIK: 0001472012 · Accession: 0000000000-23-008778
AI Filing Summary & Sentiment
File numbers found in text: 333-273792
Letter
United States securities and exchange commission logo August 11, 2023 Purnanand Sarma, Ph.D. President and Chief Executive Officer Immunome Inc. 665 Stockton Drive, Suite 300 Exton, Pennsylvania 19341 Re:Immunome Inc. Registration Statement on Form S-4 Filed August 8, 2023 File No. 333-273792 Dear Purnanand Sarma: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel Bagliebter
Show Raw Text
United States securities and exchange commission logo
August 11, 2023
Purnanand Sarma, Ph.D.
President and Chief Executive Officer
Immunome Inc.
665 Stockton Drive, Suite 300
Exton, Pennsylvania 19341
Re:Immunome Inc.
Registration Statement on Form S-4
Filed August 8, 2023
File No. 333-273792
Dear Purnanand Sarma:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel Bagliebter